首页> 外文OA文献 >Effects of Liposomal Formulation of Citicoline in Experimental Diabetes-Induced Retinal Neurodegeneration
【2h】

Effects of Liposomal Formulation of Citicoline in Experimental Diabetes-Induced Retinal Neurodegeneration

机译:Citicoline对实验糖尿病诱导的视网膜神经变性的脂质体制性的影响

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Diabetic retinopathy (DR) has been classically considered a microcirculatory disease of the retina. However, there is growing evidence to suggest that retinal neurodegeneration is also an early event in the pathogenesis of DR. Citicoline has been successfully used as a neuroprotective agent in the treatment of glaucoma but their effects on DR remain to be elucidated. On this basis, the main aim of the present study was to evaluate the effect of topical administration of citicoline in liposomal formulation on retinal neurodegeneration in db/db mouse and to investigate the underlying mechanisms of action. The treatment (citicoline or vehicle) was topically administered twice daily for 15 days. Retinal analyses were performed in vivo by electroretinography and ex vivo by using Western blot and immunofluorescence measurements. We found that the liposomal formulation of citicoline prevented glial activation and neural apoptosis in the diabetic retina. The main mechanism implicated in these beneficial effects were the inhibition of the downregulation of synaptophysin and its anti-inflammatory properties by means of preventing the upregulation of NF-κB and TNF-α (Tumor Necrosis Factor α) induced by diabetes. Overall, these results suggest that topical administration of citicoline in liposomal formulation could be considered as a new strategy for treating the early stages of DR.
机译:糖尿病视网膜病变(DR)经典被认为是视网膜的微循环疾病。然而,越来越有证据表明视网膜神经变性也是博士发病机制中的早期事件。 Citicoline已成功用作神经保护剂,治疗青光眼,但它们对DR的影响仍然阐明。在此基础上,本研究的主要目的是评估液相血酮在DB / DB小鼠视网膜神经变性对脂质体制剂中的局部施用的影响,并研究了潜在的作用机制。治疗(Citicoline或载体)每天两次局部施用15天。通过使用蛋白质印迹和免疫荧光测量,通过电测绘术和离体进行视网膜分析。我们发现患有Citicoline的脂质体制型在糖尿病视网膜中预防胶质激活和神经细胞凋亡。涉及这些有益效果的主要机制是通过预防糖尿病诱导的NF-κB和TNF-α(肿瘤坏死因子α)的上调来抑制突触蛋白和抗炎特性的下调。总体而言,这些结果表明,液体化制剂中的局部施用Citicoline可以被认为是治疗DR的早期阶段的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号